UBS Group AG Buys 220,487 Shares of MBX Biosciences, Inc. $MBX

UBS Group AG grew its stake in MBX Biosciences, Inc. (NASDAQ:MBX) by 363.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 281,212 shares of the company’s stock after acquiring an additional 220,487 shares during the quarter. UBS Group AG owned 0.63% of MBX Biosciences worth $8,869,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. CWM LLC boosted its holdings in MBX Biosciences by 28.9% in the fourth quarter. CWM LLC now owns 1,784 shares of the company’s stock worth $56,000 after acquiring an additional 400 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of MBX Biosciences in the fourth quarter worth $28,000. Russell Investments Group Ltd. raised its stake in shares of MBX Biosciences by 4,131.4% in the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock worth $26,000 after purchasing an additional 1,446 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of MBX Biosciences by 117.9% in the third quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock worth $51,000 after purchasing an additional 1,567 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new position in shares of MBX Biosciences in the third quarter worth $27,000.

Analyst Ratings Changes

Several research firms have recently weighed in on MBX. Barclays boosted their price target on MBX Biosciences from $66.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Lifesci Capital upgraded MBX Biosciences to a “strong-buy” rating in a research note on Tuesday, March 31st. UBS Group restated a “buy” rating on shares of MBX Biosciences in a research note on Tuesday, February 24th. Stifel Nicolaus set a $56.00 price target on MBX Biosciences in a research note on Tuesday, May 12th. Finally, Citigroup restated an “outperform” rating on shares of MBX Biosciences in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $60.22.

MBX Biosciences Stock Performance

MBX Biosciences stock opened at $32.45 on Monday. The stock has a market cap of $1.54 billion, a PE ratio of -14.68 and a beta of 0.78. MBX Biosciences, Inc. has a one year low of $9.43 and a one year high of $45.85. The stock has a fifty day moving average of $31.48 and a 200 day moving average of $31.94.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.15. As a group, sell-side analysts predict that MBX Biosciences, Inc. will post -2.84 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO P. Kent Hawryluk acquired 18,500 shares of MBX Biosciences stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average price of $28.41 per share, for a total transaction of $525,585.00. Following the completion of the transaction, the chief executive officer owned 486,777 shares in the company, valued at $13,829,334.57. The trade was a 3.95% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.